{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:51:34Z","timestamp":1790898694265,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF2016_10355"],"award-info":[{"award-number":["KWF2016_10355"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["Kika-295"],"award-info":[{"award-number":["Kika-295"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["KiKa-335"],"award-info":[{"award-number":["KiKa-335"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Protein kinase inhibitors are amongst the most successful cancer treatments, but targetable kinases activated by genomic abnormalities are rare in T cell acute lymphoblastic leukemia. Nevertheless, kinases can be activated in the absence of genetic defects. Thus, phosphoproteomics can provide information on pathway activation and signaling networks that offer opportunities for targeted therapy. Here, we describe a mass spectrometry-based global phosphoproteomic profiling of 11\u2009T cell acute lymphoblastic leukemia cell lines to identify targetable kinases. We report a comprehensive dataset consisting of 21,000 phosphosites on 4,896 phosphoproteins, including 217 kinases. We identify active Src-family kinases signaling as well as active cyclin-dependent kinases. We validate putative targets for therapy ex vivo and identify potential combination treatments, such as the inhibition of the INSR\/IGF-1R axis to increase the sensitivity to dasatinib treatment. Ex vivo validation of selected drug combinations using patient-derived xenografts provides a <jats:italic>proof-of-concept<\/jats:italic> for phosphoproteomics-guided design of personalized treatments.<\/jats:p>","DOI":"10.1038\/s41467-022-28682-1","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T11:10:45Z","timestamp":1645787445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1373-513X","authenticated-orcid":false,"given":"Valentina","family":"Cordo\u2019","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4146-3947","authenticated-orcid":false,"given":"Mariska T.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1622-6293","authenticated-orcid":false,"given":"Rico","family":"Hagelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"de Goeij-de Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera M.","family":"Poort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Henneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander R.","family":"Piersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0333-2492","authenticated-orcid":false,"given":"Thang V.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6212-8574","authenticated-orcid":false,"given":"Adolfo A.","family":"Ferrando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido J. R.","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie R.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6860-798X","authenticated-orcid":false,"given":"Jules P. P.","family":"Meijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"28682_CR1","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","volume":"36","author":"SS Winter","year":"2018","unstructured":"Winter, S. S. et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children\u2019s Oncology Group AALL0434 methotrexate randomization. J. Clin. Oncol. 36, 2926\u20132934 (2018).","journal-title":"J. Clin. Oncol."},{"key":"28682_CR2","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.01692","volume":"37","author":"S Jeha","year":"2019","unstructured":"Jeha, S. et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. J. Clin. Oncol. 37, 3377\u20133391 (2019).","journal-title":"J. Clin. Oncol."},{"key":"28682_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrc.2016.63","volume":"16","author":"L Belver","year":"2016","unstructured":"Belver, L. & Ferrando, A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat. Rev. Cancer 16, 494\u2013507 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"28682_CR4","doi-asserted-by":"publisher","first-page":"100647","DOI":"10.1016\/j.jbior.2019.100647","volume":"74","author":"JCG van der Zwet","year":"2019","unstructured":"van der Zwet, J. C. G., Cordo, V., Cante-Barrett, K. & Meijerink, J. P. P. Multi-omic approaches to improve outcome for T-cell acute lymphoblastic leukemia patients. Adv. Biol. Regul. 74, 100647 (2019).","journal-title":"Adv. Biol. Regul."},{"key":"28682_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/leu.2008.278","volume":"23","author":"C Graux","year":"2009","unstructured":"Graux, C. et al. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia 23, 125\u2013133 (2009).","journal-title":"Leukemia"},{"key":"28682_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3324\/haematol.2015.130179","volume":"100","author":"C Vicente","year":"2015","unstructured":"Vicente, C. et al. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica 100, 1301\u20131310 (2015).","journal-title":"Haematologica"},{"key":"28682_CR7","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211\u20131218 (2017).","journal-title":"Nat. Genet."},{"key":"28682_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1158\/2159-8290.CD-12-0504","volume":"3","author":"T Sanda","year":"2013","unstructured":"Sanda, T. et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 3, 564\u2013577 (2013).","journal-title":"Cancer Discov."},{"key":"28682_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bjh.14563","volume":"177","author":"K Akahane","year":"2017","unstructured":"Akahane, K. et al. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. Br. J. Haematol. 177, 271\u2013282 (2017).","journal-title":"Br. J. Haematol."},{"key":"28682_CR10","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.4161\/cc.29267","volume":"13","author":"AM Sparta","year":"2014","unstructured":"Sparta, A. M. et al. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. Cell Cycle 13, 2237\u20132247 (2014).","journal-title":"Cell Cycle"},{"key":"28682_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ccell.2020.01.001","volume":"37","author":"J Jiang","year":"2020","unstructured":"Jiang, J. et al. Direct phosphorylation and stabilization of MYC by Aurora B kinase promote T-cell leukemogenesis. Cancer Cell 37, 200\u2013215 (2020).","journal-title":"Cancer Cell"},{"key":"28682_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/2643-3230.BCD-20-0093","volume":"2","author":"V Cordo","year":"2021","unstructured":"Cordo, V., van der Zwet, J. C. G., Cant\u00e9-Barrett, K., Pieters, R. & Meijerink, J. P. P. T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies. Blood Cancer Discov. 2, 19\u201331 (2021).","journal-title":"Blood Cancer Discov."},{"key":"28682_CR13","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1182\/blood.2019003880","volume":"135","author":"R De Smedt","year":"2020","unstructured":"De Smedt, R. et al. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood 135, 1685\u20131695 (2020).","journal-title":"Blood"},{"key":"28682_CR14","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1038\/s41375-018-0046-8","volume":"32","author":"CL Furness","year":"2018","unstructured":"Furness, C. L. et al. The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia. Leukemia 32, 1984\u20131993 (2018).","journal-title":"Leukemia"},{"key":"28682_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nature25186","volume":"553","author":"G Tzoneva","year":"2018","unstructured":"Tzoneva, G. et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature 553, 511\u2013514 (2018).","journal-title":"Nature"},{"key":"28682_CR16","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah, N. P. et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 117, 2562\u20132569 (2007).","journal-title":"J. Clin. Invest."},{"key":"28682_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/blood-2012-04-422691","volume":"121","author":"ML Loh","year":"2013","unstructured":"Loh, M. L. et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group TARGET Project. Blood 121, 485\u2013488 (2013).","journal-title":"Blood"},{"key":"28682_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41587-019-0391-9","volume":"38","author":"M Hijazi","year":"2020","unstructured":"Hijazi, M., Smith, R., Rajeeve, V., Bessant, C. & Cutillas, P. R. Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring. Nat. Biotechnol. 38, 493\u2013502 (2020).","journal-title":"Nat. Biotechnol."},{"key":"28682_CR19","first-page":"383","volume":"9","author":"PR Cutillas","year":"2015","unstructured":"Cutillas, P. R. Role of phosphoproteomics in the development of personalized cancer therapies. Proteomics 9, 383\u2013395 (2015).","journal-title":"Proteomics"},{"key":"28682_CR20","first-page":"e1800113","volume":"13","author":"S Doll","year":"2019","unstructured":"Doll, S., Gnad, F. & Mann, M. The case for proteomics and phospho-proteomics in personalized cancer medicine. Proteomics 13, e1800113 (2019).","journal-title":"Proteomics"},{"key":"28682_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17336-9","volume":"11","author":"M Frejno","year":"2020","unstructured":"Frejno, M. et al. Proteome activity landscapes of tumor cell lines determine drug responses. Nat. Commun. 11, 3639 (2020).","journal-title":"Nat. Commun."},{"key":"28682_CR22","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1074\/mcp.RA119.001504","volume":"19","author":"C van Alphen","year":"2020","unstructured":"van Alphen, C. et al. Phosphotyrosine-based phosphoproteomics for target identification and drug response prediction in AML cell lines. Mol. Cell Proteom. 19, 884\u2013899 (2020).","journal-title":"Mol. Cell Proteom."},{"key":"28682_CR23","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/s41375-018-0032-1","volume":"32","author":"P Casado","year":"2018","unstructured":"Casado, P. et al. Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. Leukemia 32, 1818\u20131822 (2018).","journal-title":"Leukemia"},{"key":"28682_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/leu.2017.13","volume":"31","author":"V Serafin","year":"2017","unstructured":"Serafin, V. et al. Phosphoproteomic analysis reveals hyperactivation of mTOR\/STAT3 and LCK\/Calcineurin axes in pediatric early T-cell precursor ALL. Leukemia 31, 1007\u20131011 (2017).","journal-title":"Leukemia"},{"key":"28682_CR25","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/leu.2017.276","volume":"32","author":"S Degryse","year":"2018","unstructured":"Degryse, S. et al. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK\/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32, 788\u2013800 (2018).","journal-title":"Leukemia"},{"key":"28682_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22787-9","volume":"12","author":"G Franciosa","year":"2021","unstructured":"Franciosa, G. et al. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures. Nat. Commun. 12, 2507 (2021).","journal-title":"Nat. Commun."},{"key":"28682_CR27","doi-asserted-by":"publisher","first-page":"e8250","DOI":"10.15252\/msb.20198981","volume":"15","author":"R Beekhof","year":"2019","unstructured":"Beekhof, R. et al. INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases. Mol. Syst. Biol. 15, e8250 (2019).","journal-title":"Mol. Syst. Biol."},{"key":"28682_CR28","first-page":"D1153","volume":"48","author":"P Samaras","year":"2020","unstructured":"Samaras, P. et al. ProteomicsDB: a multi-omics and multi-organism resource for life science research. Nucleic Acids Res. 48, D1153\u2013D1163 (2020).","journal-title":"Nucleic Acids Res."},{"key":"28682_CR29","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1126\/science.aan4368","volume":"358","author":"S Klaeger","year":"2017","unstructured":"Klaeger, S. et al. The target landscape of clinical kinase drugs. Science. 358, 6367 (2017).","journal-title":"Science"},{"key":"28682_CR30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav, B., Wennerberg, K., Aittokallio, T. & Tang, J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 13, 504\u2013513 (2015).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"28682_CR31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard, C. et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 7, 586\u2013595 (2017).","journal-title":"Cancer Discov."},{"key":"28682_CR32","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","volume":"4","author":"J Marquart","year":"2018","unstructured":"Marquart, J., Chen, E. Y. & Prasad, V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 4, 1093\u20131098 (2018).","journal-title":"JAMA Oncol."},{"key":"28682_CR33","doi-asserted-by":"publisher","first-page":"e16711","DOI":"10.1200\/JCO.2020.38.15_suppl.e16711","volume":"38","author":"E Villa","year":"2020","unstructured":"Villa, E. et al. Phase IIa safety and efficacy of milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients. J. Clin. Oncol. 38, e16711\u2013e16711 (2020).","journal-title":"J. Clin. Oncol."},{"key":"28682_CR34","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas, V. et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129, e26\u2013e37 (2017).","journal-title":"Blood"},{"key":"28682_CR35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","volume":"2","author":"Y Gocho","year":"2021","unstructured":"Gocho, Y. et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2, 284\u2013299 (2021).","journal-title":"Nat Cancer"},{"key":"28682_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jprot.2017.08.015","volume":"170","author":"S Vyse","year":"2018","unstructured":"Vyse, S. et al. Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib. J. Proteom. 170, 130\u2013140 (2018).","journal-title":"J. Proteom."},{"key":"28682_CR37","doi-asserted-by":"publisher","first-page":"272ra212","DOI":"10.1126\/scitranslmed.3010445","volume":"7","author":"ER Zanella","year":"2015","unstructured":"Zanella, E. R. et al. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Sci. Transl. Med. 7, 272ra212 (2015).","journal-title":"Sci. Transl. Med."},{"key":"28682_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.neo.2015.03.001","volume":"17","author":"X Wan","year":"2015","unstructured":"Wan, X., Yeung, C., Heske, C., Mendoza, A. & Helman, L. J. IGF-1R inhibition activates a YES\/SFK bypass resistance pathway: rational basis for co-targeting IGF-1R and Yes\/SFK kinase in rhabdomyosarcoma. Neoplasia 17, 358\u2013366 (2015).","journal-title":"Neoplasia"},{"key":"28682_CR39","doi-asserted-by":"publisher","first-page":"e0161158","DOI":"10.1371\/journal.pone.0161158","volume":"11","author":"S Gusscott","year":"2016","unstructured":"Gusscott, S. et al. IGF1R derived PI3K\/AKT signaling maintains growth in a subset of human T-cell acute lymphoblastic leukemias. PLoS ONE 11, e0161158 (2016).","journal-title":"PLoS ONE"},{"key":"28682_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.04.030","volume":"456","author":"APN Rodrigues Alves","year":"2019","unstructured":"Rodrigues Alves, A. P. N. et al. IGF1R\/IRS1 targeting has cytotoxic activity and inhibits PI3K\/AKT\/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Lett. 456, 59\u201368 (2019).","journal-title":"Cancer Lett."},{"key":"28682_CR41","doi-asserted-by":"publisher","first-page":"E1016","DOI":"10.1073\/pnas.1520245113","volume":"113","author":"TA Triplett","year":"2016","unstructured":"Triplett, T. A. et al. Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation. Proc. Natl Acad. Sci. USA 113, E1016\u2013E1025 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28682_CR42","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1182\/blood.2020007145","volume":"136","author":"A Lyu","year":"2020","unstructured":"Lyu, A. et al. Tumor-associated myeloid cells provide critical support for T-ALL. Blood 136, 1837\u20131850 (2020).","journal-title":"Blood"},{"key":"28682_CR43","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1182\/blood-2017-05-784603","volume":"130","author":"V Serafin","year":"2017","unstructured":"Serafin, V. et al. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood 130, 2750\u20132761 (2017).","journal-title":"Blood"},{"key":"28682_CR44","first-page":"1056","volume":"106","author":"Y Shi","year":"2021","unstructured":"Shi, Y. et al. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia. Haematologica. 106, 1056\u20131066 (2021).","journal-title":"Haematologica"},{"key":"28682_CR45","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1097\/HS9.0000000000000606","volume":"5","author":"DGJ Cucchi","year":"2021","unstructured":"Cucchi, D. G. J. et al. Phosphoproteomic characterization of primary AML samples and relevance for response toward FLT3-inhibitors. Hemasphere 5, e606 (2021).","journal-title":"Hemasphere"},{"key":"28682_CR46","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s43018-020-00124-1","volume":"1","author":"K Oshima","year":"2020","unstructured":"Oshima, K. et al. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nat. Cancer 1, 1113\u20131127 (2020).","journal-title":"Nat. Cancer"},{"key":"28682_CR47","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/nprot.2016.136","volume":"11","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat. Protoc. 11, 2301\u20132319 (2016).","journal-title":"Nat. Protoc."},{"key":"28682_CR48","doi-asserted-by":"publisher","first-page":"e1002200","DOI":"10.1371\/journal.pmed.1002200","volume":"13","author":"Y Li","year":"2016","unstructured":"Li, Y. et al. IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study. PLoS Med. 13, e1002200 (2016).","journal-title":"PLoS Med."},{"key":"28682_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 22, 27\u201355 (1984).","journal-title":"Adv. Enzym. Regul."},{"key":"28682_CR50","doi-asserted-by":"publisher","unstructured":"Zheng, S. et al. SynergyFinder Plus: towards a better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinformatics, https:\/\/doi.org\/10.1016\/j.gpb.2022.01.004 (2022).","DOI":"10.1016\/j.gpb.2022.01.004"},{"key":"28682_CR51","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1007\/s10637-011-9774-6","volume":"30","author":"GJ Weiss","year":"2012","unstructured":"Weiss, G. J. et al. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Invest. N. Drugs 30, 2334\u20132343 (2012).","journal-title":"Invest. N. Drugs"},{"key":"28682_CR52","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes, J. E. et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 367, 2075\u20132088 (2012).","journal-title":"N. Engl. J. Med."},{"key":"28682_CR53","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","volume":"55","author":"R Abbas","year":"2016","unstructured":"Abbas, R. & Hsyu, P. H. Clinical pharmacokinetics and pharmacodynamics of bosutinib. Clin. Pharmacokinet. 55, 1191\u20131204 (2016).","journal-title":"Clin. Pharmacokinet."},{"key":"28682_CR54","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/1078-0432.CCR-19-0090","volume":"26","author":"N Hijiya","year":"2020","unstructured":"Hijiya, N. et al. Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia. Clin. Cancer Res. 26, 812\u2013820 (2020).","journal-title":"Clin. Cancer Res."},{"key":"28682_CR55","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","volume":"31","author":"CM Zwaan","year":"2013","unstructured":"Zwaan, C. M. et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J. Clin. Oncol. 31, 2460\u20132468 (2013).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28682-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28682-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28682-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T16:10:51Z","timestamp":1669306251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28682-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["28682"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-28682-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"28 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.J.R.Z. is founder, shareholder, and managing director of Oncolines B.V. All the other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1048"}}